Gene expression patterns as predictive biomarkers in hematology-oncology: principal hurdles on the road to the clinic.
作者信息
Rázga Filip, Némethová Veronika
机构信息
Polymer Institute, SAS, Dúbravská cesta 9, 845 41 Bratislava, Slovakia
Polymer Institute, SAS, Dúbravská cesta 9, 845 41 Bratislava, Slovakia.
出版信息
Haematologica. 2017 Jan;102(1):e31-e32. doi: 10.3324/haematol.2016.157065.
Abstract
摘要
相似文献
1
Gene expression patterns as predictive biomarkers in hematology-oncology: principal hurdles on the road to the clinic.
Haematologica. 2017 Jan;102(1):e31-e32. doi: 10.3324/haematol.2016.157065.
2
[Cancer: three eras of personalized medicine].
Med Sci (Paris). 2017 Oct;33(10):905-908. doi: 10.1051/medsci/20173310024. Epub 2017 Oct 10.
3
Advances in pediatric hematology/oncology.
Curr Opin Pediatr. 2017 Feb;29(1):1-2. doi: 10.1097/MOP.0000000000000448.
4
Neonatal Hematology and Transfusion Medicine: What We Can Learn from Pediatric Oncology Groups.
Clin Perinatol. 2015 Sep;42(3):xv-xvii. doi: 10.1016/j.clp.2015.05.003.
5
Emerging translational bioinformatics: knowledge-guided biomarker identification for cancer diagnostics.
Annu Int Conf IEEE Eng Med Biol Soc. 2009;2009:4162-5. doi: 10.1109/IEMBS.2009.5333937.
6
Hematology/Oncology Emergencies.
Hematol Oncol Clin North Am. 2017 Dec;31(6):xiii-xiv. doi: 10.1016/j.hoc.2017.09.013.
7
Emerging trends in biomarker discovery: Ease of prognosis and prediction in cancer.
Semin Cancer Biol. 2018 Oct;52(Pt 1):iii-iv. doi: 10.1016/j.semcancer.2018.05.008. Epub 2018 May 29.
8
A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers.
J Clin Oncol. 2008 Dec 1;26(34):5630-7. doi: 10.1200/JCO.2008.17.3567. Epub 2008 Oct 20.
9
10
Personalized oncology: recent advances and future challenges.
Metabolism. 2013 Jan;62 Suppl 1:S11-4. doi: 10.1016/j.metabol.2012.08.016. Epub 2012 Sep 19.
引用本文的文献
1
Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review.
Cancers (Basel). 2024 Mar 30;16(7):1363. doi: 10.3390/cancers16071363.
本文引用的文献
1
MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses.
Haematologica. 2016 Nov;101(11):e454-e456. doi: 10.3324/haematol.2016.146555. Epub 2016 Jul 28.
2
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.
Leukemia. 2017 Jan;31(1):75-82. doi: 10.1038/leu.2016.179. Epub 2016 Jun 24.
3
Clinical significance of microRNAs in chronic and acute human leukemia.
Mol Cancer. 2016 May 14;15(1):37. doi: 10.1186/s12943-016-0518-2.
4
miRNAs as Biomarkers in Chronic Myelogenous Leukemia.
Drug Dev Res. 2015 Sep;76(6):278-85. doi: 10.1002/ddr.21266. Epub 2015 Aug 18.
5
OCT1 and imatinib transport in CML: is it clinically relevant?
Leukemia. 2015 Oct;29(10):1960-9. doi: 10.1038/leu.2015.170. Epub 2015 Jul 9.
6
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.
Haematologica. 2015 May;100(5):e183-5. doi: 10.3324/haematol.2014.118117. Epub 2015 Jan 30.
7
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.
Blood. 2013 Jan 24;121(4):628-37. doi: 10.1182/blood-2012-01-405035. Epub 2012 Dec 5.
8
Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.
Leuk Lymphoma. 2011 Feb;52(2):331-4. doi: 10.3109/10428194.2010.533220. Epub 2010 Dec 6.
9
OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.
Haematologica. 2011 Feb;96(2):213-20. doi: 10.3324/haematol.2010.033290. Epub 2010 Oct 22.
10
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.
Am J Hematol. 2010 Jul;85(7):525-8. doi: 10.1002/ajh.21722.
Zotero 插件